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Cancer Therapy: Preclinical
Carbonic Anhydrase IX Promotes Tumor Growth and
Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
Alan McIntyre1, Shalini Patiar1, Simon Wigﬁeld1, Ji-liang Li1, Ioanna Ledaki1, Helen Turley1,3,
Russell Leek1,3, Cameron Snell1,3, Kevin Gatter3, William S. Sly4, Richard D. Vaughan-Jones2,
Pawel Swietach2, and Adrian L. Harris1
Abstract
Purpose: Bevacizumab, an anti-VEGFA antibody, inhibits the developing vasculature of tumors, but
resistance is common. Antiangiogenic therapy induces hypoxia and we observed increased expression of
hypoxia-regulated genes, including carbonic anhydrase IX (CAIX), in response to bevacizumab treatment in
xenografts. CAIX expression correlates with poor prognosis inmost tumor types andwith worse outcome in
bevacizumab-treated patients with metastatic colorectal cancer, malignant astrocytoma, and recurrent
malignant glioma.
Experimental Design: We knocked down CAIX expression by short hairpin RNA in a colon cancer
(HT29) and a glioblastoma (U87) cell line which have high hypoxic induction of CAIX and overexpressed
CAIX in HCT116 cells which has low CAIX. We investigated the effect on growth rate in three-dimensional
(3D) culture and in vivo, and examined the effect of CAIX knockdown in combination with bevacizumab.
Results:CAIX expressionwas associatedwith increased growth rate in spheroids and in vivo. Surprisingly,
CAIX expression was associated with increased necrosis and apoptosis in vivo and in vitro. We found that
acidity inhibits CAIX activity over the pH range found in tumors (pK ¼ 6.84), and this may be the
mechanismwhereby excess acid self-limits the build-up of extracellular acid. Expression of another hypoxia
inducible CA isoform, CAXII, was upregulated in 3D but not two-dimensional culture in response to CAIX
knockdown. CAIX knockdown enhanced the effect of bevacizumab treatment, reducing tumor growth rate
in vivo.
Conclusion: This work provides evidence that inhibition of the hypoxic adaptation to antiangiogenic
therapy enhances bevacizumab treatment and highlights the value of developing small molecules or
antibodies which inhibit CAIX for combination therapy. Clin Cancer Res; 18(11); 3100–11. 2012 AACR.
Introduction
The increased metabolic production, and impaired
removal, of CO2 and lactic acid can result in a highly acidic
extracellular microenvironment (1, 2). Adaptation to this is
crucial for cancer progression (3). Hypoxia-inducible factor
(HIF), coordinates a shift in gene expression pattern, as part
of the hypoxic response (4, 5). This includes increased
expression of extracellular carbonic anhydrases IX (CAIX)
and XII (CAXII; ref. 6). CAIX andCAXII expression has been
identified in numerous cancer types and are generally
associatedwithhypoxia (7–11).CA9 expression is regulated
by HIF-1a where the HRE/HIF-1a–binding site is located
at 3 of 10 position in the promoter region of this gene
(6, 12). CAIX and CAXII facilitate transmembrane removal
of CO2 (a weak acid) by hydrating extracellular CO2 and
thereby maintaining a steeper efflux gradient (13). We
recently identified a major role for CAIX in regulating
intracellular and extracellular pH in spheroids (14). CAIX
expression maintained a more alkaline and uniform intra-
cellular pH while producing a more acidic extracellular pH
(14). We identified that the majority of cellular acid is
excreted across the membrane in the form of CO2 rather
than lactic acid (15), highlighting the importance of extra-
cellular CAs in maintaining favorable intracellular pH.
The expression of CAIX is restricted in normal adult tissues
(16, 17) and disruption of the mouse homolog of CAIX
during development resulted in only gastric hyperplasia
(18), therefore making it a good therapeutic target. CAIX is
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a marker for poor clinical outcome in most cancer types
(10, 19–21).
There is evidence of resistance to therapy in almost all
anti-VEGF clinical trials (22, 23). Resistance mechanisms
may include vascular regrowth due to additional proangio-
genic factors such as Delta-like ligand 4 (DLL4; ref. 24);
protection of the tumor vasculature by increasing recruit-
ment of pericytes, which densely cover vessels or proangio-
genic inflammatory cells, such as proangiogenic monocytic
cells; or through co-opting normal vasculature by increased
invasion into local tissues as reviewed by Bergers and
Hanahan (25). In addition, antiangiogenic therapies induce
hypoxia (26). This is likely to promote selection or adap-
tation of cells able to proliferate and survive in oxygen- and
nutrient-deficient environments. Hypoxic adaptation
occurs through HIF-1a stabilization and increased target
gene expression. This hypoxic response could provide a
further mechanism of resistance enabling tumors to over-
come increased hypoxic conditions. CAIX expression was
associated with poorer clinical outcome in response to
antiangiogenic therapy (bevacizumab) in patients with
metastatic colorectal cancer (27), malignant astrocytoma
(28), and with worse progression-free survival in recurrent
malignant glioma (29). VEGF, the target of bevacizumab
and another target gene of HIF-1a, was not associated with
worse outcome in these studies (27–29). These data suggest
that CAIXmay contribute to this angiogenesis-independent
mechanism of resistance.
Two recent investigations of the role of CAIX in xenograft
growth showed thatCAIXknockdownby short hairpinRNA
(shRNA) reduced xenograft tumor volume in one colon
cancer cell line (30), one mouse breast cancer cell line, and
one human breast cancer cell line (31). One of these studies
showed upregulated CAXII expression in response to CAIX
knockdown (26), where dual knockdown of both CAIX
and CAXII reduced xenograft growth further (30). In this
study, we constitutively knocked down CAIX expression in
HT29 which have high levels of hypoxia-induced CAIX,
to enable analysis of CAIX function. Conversely, we over-
expressedCA9 in HCT116which have low levels of hypoxic
CAIX and CAXII.
We found that the capacity of CAIX to hydrate CO2 is
negatively affected by acidity, thereby producing a self-
limitingmechanism if excess acid accumulates. Overexpres-
sion of CAIX in HCT116 increased spheroid and xenograft
growth rate. CAIX knockdown in HT29 cells reduced spher-
oid and xenograft growth rate. Surprisingly, CAIX expres-
sion increased necrosis in spheroids and xenografts (HT29
and HCT116) and increased markers for apoptosis in
spheroids (HT29 and HCT116) and in vivo (HT29). CAIX
expression also increased Ki-67 staining, a marker for pro-
liferation (HT29). CAXII expression was upregulated in
response to CAIX knockdown in spheroids and xenografts
although not in 2-dimensional (2D) culture. We identified
increasedCA9 expression in response to bevacizumab treat-
ment in U87 (glioblastoma cell line) xenografts. Further-
more, we investigated the role of CAIX in resistance to
bevacizumab treatment in HT29 and U87 xenografts. The
results show an enhanced effect, significantly reducing
growth rate.
Materials and Methods
Cell culture
Cells were maintained in a humidified incubator at 5%
CO2 and 37
C. For hypoxic exposure, cells were grown at
0.1% O2, 5% CO2, and 37
C. HCT116 were maintained in
McCoy’s 5A while HT29 and U87 were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) both sup-
plemented with 10% FBS. For spheroid culture, aggregation
was initiated by resuspending 4  106 cells in 250 mL of
medium in 1 L spinner flasks (TechneMCS) spun at 40 rpm
at 37C, 5% CO2 or as described previously (32).
Stable transfection
The following constructs were used to generate stable cell
lines: human CA9 cDNA (FLCA9; a gift from Dr. Jaromir
Pastorek, Slovak Academy of Science, Bratislava, Slovak
Republic) was cloned into pcDNA3.1(þ) (Invitrogen).
To knockdown CA9 in HT29, the HuSH-29 shRNA target-
ing CA9 (TR314250) and empty vector (R20003) were
purchased from Origene. Cell lines were transfected
with FuGENE 6 (Roche) according to manufacturer’s in-
structions. To knockdownCA9 in U87 a doxycycline induc-
ible shCA9 (V3THS_363219) and shControl (shCTL;
RHS4743) vectors were purchased from Thermo Scientific
and lentivirus produced by the trans-lenti shRNApackaging
kit (TLP4615) and cells transduced according to manu-
facturers instructions (Thermo Scientific). Cells were grown
under selective pressure [HCT116, 0.4 mg/mL G418 (Invi-
trogen); HT29, 300 ng/mL puromycin; U87, 1 mg/mL
puromycin (Invitrogen)] until no mock-transfected cells
Translational Relevance
Although antiangiogenic therapy represents an impor-
tant therapeutic strategy in cancer treatment, resistance is
common. We identify increased expression of hypoxia-
regulated CAIX in response to bevacizumab in xeno-
grafts. CAIX is amarker of poor prognosis inmost tumor
types and worse outcome in response to bevacizumab
treatment. We showed that CAIX expression increased
growth rate in xenografts, with increased expression of
Ki-67 specifically in hypoxic areas of spheroids. CAIX
was also associated with increased necrosis, a poor
prognostic marker in many tumor types. We hypothe-
sized that inhibiting this important hypoxia adaptation
mechanism for regulating pH stress would sensitize cells
to bevacizumab treatment. Indeed, CAIX knockdown or
inhibition enhanced antiangiogenic therapy. This work
shows the principle of targeting tumor hypoxic response
mechanisms in combination with antiangiogenic ther-
apy and highlights CAIX as a therapeutic target alone or
in combination with anti-VEGF therapy.
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remained. Individual clones were isolated with cloning
cylinders (Sigma).
Immunoblotting
Cell lysates were separated on 10% SDS-PAGE and trans-
ferred to polyvinylidene difluoride membrane. Primary
antibodies were used at 1:1,000 unless otherwise stated.
These were mouse anti-HIF-1a, (BD Transduction Labora-
tories), mouse anti-CA9 (Gift from J. Pastorek, Institute of
Virology, Slovak Republic), goat anti-CA12 (R&DSystems),
mouse anti-Naþ/Kþ-ATPase (1:5,000; Abcam), and mouse
anti-b-tubulin (Sigma). Appropriate secondary horseradish
peroxidase (HRP)-linked antibodies were used (Dako).
Immunoreactivity was detected with chemiluminescence
(Amersham).
Quantitative PCR
RNA extraction and the quantitative PCR protocol
have been described previously (33). Primer sequen-
ces: CA9 forward, CTTGGAAGAAATCGCTGAGG; CA9
reverse, TGGAAGTAGCGGCTGAAGTC; CA12 forward,
GCTCTGAGCACACCGTCA; CA12 reverse, GGATAAAGG-
TCTGAGTTATAATGGACA; glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) forward, AGCCACATCGCTCA-
GACAC; GAPDH reverse, GCCCAATACGACCAAATCC.
Flow cytometry
Cells were detached and resuspended on ice in 100 mL of
PBS, at a concentration of 2  106 cells per mL. Ten
microliters of FITC Labeled CAIX (R&D systems) or isotype
IgG antibody (R&D systems) was added and incubated for
1 hour at 4C. Cells were washedwith PBS and resuspended
in 500 mL of PBS. Samples were analyzed by flow cytometry
using a FACSCalibur flow cytometer (BD Biosciences) and
CellQuest software (BD Biosciences).
CA activity assay
HCT116 cells were harvested to a total cell count of the
order 107 to 108 inHEPES-bufferedDMEM.Cellswere lysed
in 20 mmol/L HEPES, 20 mmol/L Mes, protease inhibitor
(Roche), 30mmol/L KCl, 0.5% Triton X, and a pH adjusted
to the desired starting point between 6.5 and 8. The mem-
brane fraction was separated from the cytosolic fraction by
centrifugation at 100,000 rpm for 40 minutes. The pellet,
containing the membrane fraction, was resuspended in
fresh lysis buffer. The total CA activity was measured by a
kinetic assay (as previously described; ref. 14). The pH
sensitivity of CA activity was elucidated by adjusting lysis
buffer pH to6.5, 7.0, 7.5, and8.0. CAactivitywas quantified
relative to the spontaneous rate measured in lysis buffer
only or in extracts treated with the broad spectrum CA
inhibitor, acetazolamide (100 mmol/L). The CO2 hydration
rate constant was estimated by fitting experimental pH
time courses with model predictions, run for different rate
constants. The model consisted of 3 ordinary differential
equations for pH, CO2, and HCO3
 and included pH
sensitivity of the CO2 hydration rate constant. Kinetic data
were normalized to the protein content (per 1 mg/mL),
measured by the Bradford assay (Biorad). The pH depen-
dence of CA activity was fitted with a Hill equation, featur-
ing the spontaneous hydration rate (kspont), the maximum
catalyzed activity (kmax), half-maximal pH (pK), and coop-
erativity (n or Hill number):
khydration ¼ kspont þ kmax 
10pK
 n
10pHð Þnþ 10pKð Þn
Xenograft studies
Mice were housed at Cancer Research UK Laboratories
(Clare Hall) and procedures were carried out under a Home
Office license. Cells were trypsinized and washed twice in
serum-free medium before inoculation in mice. Six- to
7-week-old female BALB/c nu/nu mice were injected subcu-
taneously in the lower flank with 100 mL Matrigel (BD Bio-
science) and 1 107 cells suspended in 100 mL of serum-free
medium. Tumor growth was monitored 3 times per week
measuring the length (L), width (W), and height (H) of each
tumor with calipers. Volumes were calculated from the for-
mula 1/6 p LWH. When tumors reached 1.44 cm3
the mice were sacrificed by cervical dislocation. Ninety min-
utes before sacrifice, mice were injected intravenously with
2 mg of pimonidazole (hypoxyprobe-1; Chemicon Interna-
tional) as described previously (24). For bevacizumab treat-
ment mice were injected intraperitoneally every 3 days
(10 mg/kg), until sacrifice, once 2 of 5 mice from any group
had xenografts which had reached 150mm3 in size. If requir-
ed, doxycycline was given through the feed at 625 mg/kg
ad libitum (SDS services) from the start of the experiment.
Immunohistochemistry
Immunohistochemistry was carried out as previously
described (24). The following primary antibodies were used
at room temperature for 1 hour; CAIX (M75, 1:50); HIF-1
(BD Biosciences; 1:100); pimonidazole (hypoxyprobe-1;
Chemicon International; 1:50); CD34 (MCA1825; AbD
Serotec; 1:50), cleaved caspase-3 (RnD systems; 1:2,000),
CAXII (1:1,000; ref. 34), and Ki-67 (M7240; Dako; 1:50).
Slides were incubated with the anti-rabbit/anti-mouse sec-
ondary antibody(Dako) for30minutes at roomtemperature
and washed in PBS. 3,30-Diaminobenzidine (DAB; Dako)
was applied to the sections for 7 minutes. The slides were
counterstained by immersing in hematoxylin solution (Sig-
ma-Aldrich) for 20 seconds and mounted with Aquamount
(VWR). Secondary-only control stainingwas done routinely,
these were negative. One section from each xenograft was
analyzed for each stain. Slides were scored by 2 researchers
blinded to groupings (as a percentage or index based on
intensity and percentage positive) or analyzed quantitatively
by image analysis in imageJ using color deconvolution as
described previously (35). Where scores differed, sections
were reviewed and a consensus result was decided.
Statistics
Statistical analysis including the Student t test, one-way
ANOVA, and linear regressionof log transformed growthdata
were carried out as appropriate with GraphPad Prism 4.0b.
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Results
Validation of stable transfectants
HCT116 cells were transfected with the CA9 coding
sequence (FLCA9) or empty vector (EV). CAIX was over-
expressed relative to empty vector shown by immunoblot
and flow cytometry (Fig. 1A).
HT29 was transfected with an shRNA targeting CA9
(shCA9) or empty vector. CAIX knockdown in shCA9 was
shown by quantitative PCR and immunoblot compared
with empty vector (Fig. 1B). The expression of CA9 in
shCA9 was 6% the empty vector levels at 0.1% O2 for
72 hours (, P < 0.001, n ¼ 3).
U87 cells were transduced with an shCA9 or a non-
targeting shRNA (shCTL). CA9 knockdown in shCA9 was
shown by quantitative PCR (, P < 0.001, n ¼ 3; Fig. 1C)
and by immunoblotting at a range of doxycycline concen-
trations (Fig. 1D).
Acidity inhibits CAIX activity in vitro in HCT116
HCT116 FLCA9 and empty vector membrane extracts
were prepared and tested for CA activity. The subcellular
fractionation was assessed by immunoblotting the
membrane fraction for Naþ/Kþ-ATPase, a membrane-
specific protein (Fig. 1E). Membrane extracts from empty
Figure 1. Analysis of CAIX
expression and activity. A, CAIX
expression in HCT116 clones by
immunoblot (top) and ﬂuorescence-
activated cell-sorting (FACS)
analysis (bottom). B, CA9 and CA12
expression in HT29 in normoxic and
0.1% O2 (top). , P < 0.001;
, P < 0.05, n ¼ 3, hypoxia. CAIX and
CAXII expression in normoxic and
0.1% O2, 72 hours (bottom).
C,CA9 expression in U87 shCTL and
shCA9 pools in normoxia and
0.1% O2 (hypoxia; 72 hours)
measured by (C) quantitative PCR
and (D) immunoblot. E, immunoblot
of cytoplasmic (C) andmembrane (M)
fraction of HCT116 clones.
F, CO2 hydration rate constant of
HCT116 clones at a range of
pH  acetazolomide (ATZ).
Immunoblots are representative of
3 blots. Error bars represent SD.
FITC, ﬂuorescein isothiocyanate.
Carbonic Anhydrase IX Inhibition Enhances Anti-VEGF Therapy
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vector cells showed hydration at the spontaneous
rate, with similar CO2 hydration rates in the presence
of acetazolamide, a CA inhibitor. In FLCA9, CAIX was
catalytically active in the membrane fraction and inhi-
bition to basal empty vector levels occurred in the pres-
ence of acetazolamide. CA activity was markedly reduced
by decreasing pH, with CA activity almost completely
inhibited at pH 6.0 and a pK (pH for half-maximum
rate) between 6.81 and 6.86 (Fig. 1F). Best-fitting Hill
curves to the pH-sensitivity data yielded Hill cooperat-
ivity numbers near 2 for full-length CAIX. As a conse-
quence of this, the pH sensitivity of CAIX to pH is steeper
than for other CA isoforms (36).
CAIX expression increases growth rate in 3D culture
and in vivo
We found a significant increase in growth rate inHCT116
FLCA9 spheroids (, P < 0.001, n ¼ 3; Fig. 2A) and
xenografts (, P < 0.001, n ¼ 10; Fig. 2B) compared with
empty vector.
CAIX knockdown reduced the growth rate of HT29
spheroids (, P < 0.05, n ¼ 3; Fig. 2C) and xenografts
(, P < 0.05, n ¼ 5; Fig. 2D) compared with empty
vector.
CAIX expression promotes necrosis, apoptosis, and
proliferation in spheroid culture and in vivo
We characterized the spheroids and xenograft tumors for
several immunohistologic markers related to cell survival
and angiogenesis.
CAIX expression
In HCT116 spheroids, the percentage of CAIX-positive
cells was greater in FLCA9 (95%) than empty vector (5%;
, P < 0.001, n ¼ 5; Fig. 3A). Similarly in HCT116
xenografts, the percentage of CAIX-positive cells was greater
in FLCA9 (FL/1, 55% and FL/3, 75.5%) than empty vector
(EV; EV/5, 12.5% and EV/6, 13.5%; , P < 0.001, n ¼
10; Fig. 4A).
In HT29 spheroids, CAIX expression was decreased in
shCA9 (2.5%) compared with empty vector (18%; , P <
0.001, n ¼ 5; Fig. 3B). The same was true in the xenografts
shCA9 (6%) compared with empty vector (17%; , P <
0.001, n ¼ 5; Fig. 4B).
Necrosis
In HCT116 spheroids, the proportion of necrosis was
higher in FLCA9 (15%) than in empty vector (5%; , P <
0.01, n ¼ 5; Fig. 3A). The proportion of necrosis was
significantly higher in FLCA9 HCT116 xenografts (FL/1,
39.5% and FL/3, 28.6%) than in empty vector (EV/5, 6.9%
and EV/6, 12.1%; , P < 0.05, n ¼ 10; Fig. 4A).
Conversely in the HT29 spheroids and xenografts, the
shCA9 had less necrosis (spheroids, 19% and xenografts,
13%) than empty vector [spheroids, 36% and xenografts,
35%; spheroids, , P < 0.001, n ¼ 5 (Fig. 3B) and xeno-
grafts, , P < 0.05, n ¼ 5 (Fig. 4B)].
Apoptosis
HCT116 FLCA9 spheroids showed increased apoptosis
compared with empty vector as determined by immunos-
taining for activated caspase-3 (2.9% and 6.0%, respective-
ly, ,P < 0.001, n¼ 5; Fig. 3A) although this was not found
in the xenografts (Fig. 4A).
Increased apoptosis was found in the HT29 empty
vector spheroids and xenografts compared with shCA9
(spheroids, 9% and 5%; , P < 0.001, n ¼ 5; Fig. 3B and
xenografts; , P < 0.05, n ¼ 5; Fig. 4B).
Figure 2. CAIX increases growth
rate in spheroids and xenografts.
A, spheroid growth curves of
HCT116 (, P < 0.001, n ¼ 3). B,
xenograft growth curves of
HCT116 (, P < 0.001, n ¼ 5). C,
spheroid growth curves of HT29
(, P < 0.05, n ¼ 3). D, xenograft
growth curves of HT29 (, P < 0.05,
n ¼ 5). Error bars represent SD.
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Ki-67
In HT29 xenografts, the percentage of Ki-67–positive
nuclei was higher in empty vector (89%) than in shCA9
(55%, , P < 0.001, n ¼ 5; Fig. 4B). In HT29 spheroids,
Ki-67 positivity was higher in hypoxic areas in empty
vector (32%) than in shCA9 (15%, , P < 0.001, n ¼
5; Fig. 5A). Hypoxic areas were defined by pimonidazole
staining. There was no difference in Ki-67 positivity in
HCT116, FLCA9 or empty vector spheroids (Fig. 3A), or
xenografts (Fig. 4A).
Pimonidazole
Reduced pimonidazole staining was associated with
CAIX expression in spheroids, HCT116 FLCA9 (15%) and
empty vector (20%, , P < 0.05, n¼ 5; Fig. 3A), HT29 empty
vector (32%), and shCA9 (55%, , P < 0.001, n ¼
5; Fig. 3B). This was due to the increase in necrosis in
hypoxic areas of CAIX-positive spheroids, which reduced
the amount of viable hypoxic tissue. CAIX expression did
not effect the distance from the edge of the spheroids that
pimonidazole staining began. There was no difference
in pimonidazole staining in xenografts in HCT116
(Fig. 4A) or in HIF-1a staining in HT29 (Fig. 4B).
CD34
CAIX expression did not affect CD34 staining, a marker
for blood vessels in xenografts in HCT116 (Fig. 4A) and
HT29 (Fig. 4B).
CAIX expression results in more viable tumor cells
CAIX increased growth rate while also increasing necro-
sis. Therefore, it was unclear whether CAIX expression
increased the amount of viable tumor tissue at a given
time point. To calculate the volume of the viable tumor,
we subtracted the percentage of necrotic tumor (deter-
mined by histology, Figs. 3 and 4) from the endpoint
volumes of the xenografts and spheroids expressing
CAIX. These viable tumor volumes of the CAIX expressors
were greater than the volumes of the spheroids and
xenografts which lacked CAIX expression at the same
Figure 3. CAIX expression is associated with increased necrosis and apoptosis in spheroid culture. A, representative immunohistochemical images
and bar chart of scoring in HCT116 FLCA9 and empty vector (EV) spheroids. CAIX expression, percentage of necrosis, percentage of pimonidazole (PIMO),
and caspase-3 staining were signiﬁcantly different between empty vector and FLCA9 spheroids. B, representative immunohistochemical images and bar
charts of scoring of HT29 empty vector and shCA9 spheroids. CAIX expression, percentage of necrosis, percentage of pimonidazole, and cleaved
caspase-3 stainingwere signiﬁcantly different between empty vector and shCA9. CAIX, pimonidazole, caspase-3, andKi-67 expression staining are shown in
dark brown. Hematoxylin and eosin (H&E), dark pink denotes viable tissue, light pink denotes necrosis. Error bars represent SD. N denotes areas of necrosis.
Arrows point to positive staining (, P < 0.001; , P < 0.01; , P < 0.05, n ¼ 5).
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time point. However, the latter were allowed to continue
to grow to assess final growth curves.
This analysis revealed that the CAIX expressors had in-
creased viable tumor volume in HCT116 xenografts (66%
more viable tumor at day 14, , P < 0.01, n ¼ 10) and
spheroids (19% more viable tumor at day 13, , P < 0.01,
n ¼ 5) and HT29 xenografts (52% more tumor tissue at
day 20, P < 0.05, n ¼ 5) and spheroids (81% more viable
tumor at day 16, , P < 0.01, n¼ 5; Supplementary Fig. S1).
Although we acknowledge a likely overestimation in the
amount of viable tumor in the CAIX-deficient groups
(HCT116 empty vector and HT29 shCA9), as necrosis was
not subtracted from these volumes, this would only make
the results more significant. Necrosis was not subtracted
from the CAIX-deficient groups (HCT116 empty vector and
HT29 shCA9) because data on the amount of necrosis was
only available at the time of sacrifice of these controls, not
the earlier date on which the CAIX expressors were ended.
CAIX knockdown increases CAXII expression in 3D
culture and in vivo but not in 2D culture in HT29
In HT29, no effect was identified on CAXII RNA or
protein levels in response toCAIX knockdown in 2D culture
(Fig. 1B). In 3-dimensional (3D) culture CAIX knock-
down increased CA12 expression at the RNA (by 2-fold,
P < 0.05, n ¼ 5; Fig. 5B) and protein level by immuno-
histochemistry (from 1% to 2% of cells; , P < 0.001,
n ¼ 5; Fig. 5D). In vivo CAIX knockdown did not increase
CA12 RNA expression (Fig. 5C) but did increase CAXII
protein expression in shCA9 (5%) compared with empty
vector (2%; , P < 0.05, n ¼ 5; Fig. 5E).
Knockdown of CAIX enhances antiangiogenic therapy
reducing growth rate in vivo
We identified that CA9 expression was increased
(,P<0.001,n¼5) in response to bevacizumab treatment
with material from a previous xenograft experiment using,
the glioblastoma cell line, U87 (ref. 24; Supplementary
Fig. S2). HT29 empty vector and shCA9 were grown as
xenografts with and without bevacizumab treatment
(Fig. 6A). The shCA9 clone grew more slowly than the
empty vector clone as before (75.9% the growth rate of the
empty vector; , P < 0.05, n ¼ 5). Bevacizumab treatment
also reduced xenograft growth rate (68% the rate of empty
vector control; , P < 0.05, n ¼ 5). The HT29 shCA9 clones
treated with bevacizumab grew significantly more slowly
Figure 4. CAIX expression is associated with increased necrosis in HCT116 xenografts and increased necrosis, apoptosis, and proliferation in HT29
xenografts. A, representative immunohistochemical images of HCT116 empty vector (EV) and FLCA9 xenografts and bar chart of scoring. CAIX
expression and proportion of necrosis were signiﬁcantly different between empty vector and FLCA9. B, representative immunohistochemical images of
HT29 empty vector and shCA9 xenografts and bar chart of scoring. CAIX expression, proportion of necrosis, cleaved caspase-3, and Ki-67 expression
were signiﬁcantly different between empty vector and shCA9. CAIX, HIF-1, cleaved caspase-3, Ki-67, and CD34 expression staining is shown in
dark brown. H&E, dark pink denotes viable tissue, the light pink stain denotes necrosis. Error bars represent SD. N denotes areas of necrosis.
Arrows point to positive staining. Scale bars represent 200 mm. Ki-67 images have a top right  20 inset image with scale bars representing 100 mm.
(, P < 0.001; , P < 0.05, n ¼ 5).
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than shCA9-untreated xenografts or empty vector be-
vacizumab-treated xenografts (37% the growth rate of
untreated empty vector; , P < 0.05, n ¼ 5; Fig. 6A). This
was at least an additive reduction in growth rate. shCA9
xenografts had reduced CAIX expression compared with
empty vector clones when treated with vehicle (PBS;
, P < 0.01, n ¼ 5) and with bevacizumab (, P < 0.001,
n¼ 5; Supplementary Fig. S3). HT29 cells were also treated
with acetazolamide in combination with bevacizumab.
Acetazolamide or bevacizumab treatment alone did not
significantly reduce growth rate however, both in combi-
nation, reduced growth significantly compared with
untreated (, P < 0.05, n¼ 5) or bevacizumab-treated alone
(, P < 0.05, n ¼ 3; Fig. 6B).
U87 xenografts with doxycycline-inducible shCA9
were treated with bevacizumab. The shCA9 without doxy-
cycline and the shCTL with or without doxycycline xeno-
grafts grew at the same rate (Fig. 6C). CA9 knockdown
(33% reduction, P < 0.05, n ¼ 5) or bevacizumab treat-
ment alone (38% reduction, P < 0.05, n ¼ 5) significantly
reduced xenografts growth rate. CA9 knockdown and
bevacizumab treatment in combination significantly
reduced growth rate further (>50%), more than CA9
knockdown (, P < 0.05, n¼ 5) or bevacizumab treatment
(, P < 0.05, n ¼ 5) alone.
Bevacizumab treatment reduced the number of blood
vessels in the HT29 xenografts as determined by CD34
staining [empty vector: P < 0.05, n ¼ 5; shCA9: P < 0.05,
Figure 5. CAIX knockdown in HT29
reduces Ki-67 positivity in the
hypoxic fraction of spheroids and
increases CAXII expression in 3D
culture and in vivo. A, examples of
HT29 empty vector (EV) and shCA9
spheroids stained for Ki-67. Red
lines denote the area of central
hypoxia. A graph of the percentage
of Ki-67 positivity inside the hypoxic
core of the HT29 empty vector and
shCA9 spheroids. B, analysis of
CA9 and CA12 RNA expression in
HT29 empty vector and shCA9
spheroids. C, analysis of CA9
and CA12 RNA expression in HT29
empty vector and shCA9
xenografts. D, analysis of
CAXII expression by
immunohistochemistry with
representative images of empty
vector and shCA9 spheroids
(top) and a bar chart of the
scoring (bottom). E, analysis
of CAXII expression by
immunohistochemistry with
representative images of empty
vector and shCA9 xenografts (top)
and a bar chart of the scoring
(bottom). CAXII expression staining
is shown in dark brown. N denotes
areas of necrosis. Arrows point to
positive staining. Scale bars
represent 100 mm. (, P < 0.001;
, P < 0.05, n ¼ 5).
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n ¼ 5; vehicle: , P < 0.05, n ¼ 5; acetazolamide (ATZ):
, P < 0.01, n ¼ 5; Supplementary Figs. S3 and S4].
Bevacizumab treatment increased the amount of hypoxia
in xenografts as determined by HIF-1a immunostaining
(empty vector: , P < 0.05, n¼ 5; shCA9: , P < 0.01, n¼ 5).
CAIX immunostaining (empty vector: , P < 0.001, n¼ 5;
vehicle: , P < 0.05, n ¼ 5; ATZ: , P < 0.01, n ¼ 5), the
amount of necrosis (shCA9: , P < 0.01, n ¼ 5) and apop-
tosis as determined by caspase-3 activation (empty vector:
, P < 0.01, n¼ 5; shCA9: , P < 0.05, n¼ 50 Supplementary
Figs. S3 and S4) was also increased with bevacizumab
treatment.
Discussion
We recently highlighted the importance of CAIX in
regulating intracellular and extracellular pH in spheroids
(14, 15, 37, 38). In addition, the proteoglycan domain of
CAIX has previously been linked to negative regulation
of cell adhesion through modulation of b-catenin and
E-cadherin interactions (39), whereas the intracellular
domain has been shown to contribute to AKT activation
(40). To understand the role of CAIX in spheroids and
in vivo,we knocked down CAIX in HT29 cells, which have
high levels of CAIX under hypoxic stress. Several cell
lines and human tumors have low levels of CAIX expres-
sion or induction by hypoxia, and the HCT116 cells
provided an opportunity to investigate the role of CAIX
when uniformly expressed in a tumor. Further to this,
we examined the role of CAIX in resistance to severe
hypoxia induced by bevacizumab treatment in HT29
and U87 cells.
We found that CAIX catalytic activity is inhibited by low
pHandwas half-maximal (i.e., the pK) at pHapproximately
6.8. This is lower than the typical value for other CA iso-
forms (36), but in the range of extracellular pHmeasured in
human tumors (pH6.5–6.8; refs. 41, 42). Consequently,Hþ
ions, produced by CO2 hydration in the tumor milieu, can
exert an important autoinhibitory effect on CAIX. The pH
dependence of CAIX activity showed a cooperativity of
approximately 2 [higher than reported for a truncated
recombinant CAIX (ref. 43) and for other CA isoforms
(ref. 36)], making CAIX activity more Hþ sensitive as pH
approaches the enzyme’s pK. CAIX’s relatively low pK will
allow the tumor to attain a more acidic extracellular pH,
whereas higher cooperativity may protect from excessive
acidification by strengthening the autoinhibitory Hþ effect
below a critical pH. Although there is pH inhibition of CAIX
activity, it is not autoinhibited abruptly, but gradually, and
therefore significant activity is still measurable at pH 6.5.
We have modeled the relationship between CA activity
and extracellular pH (15).We showed that "basal" CAIX
activity would have to be very mild to be completely
switched off by extracellular Hþ ions.
We show that CAIX knockdown reduced the growth rate
of xenografts as has been reported in 2 recent studies
(26, 31). In addition, we identify the converse, whereby
overexpression of CAIX in HCT116 increased growth rate.
However, we identified, for the first time, that CAIX expres-
sion was associated with increased necrosis. This was
Figure 6. CAIX knockdown
enhances bevacizumab treatment
in xenografts. A, xenograft
growth curves of HT29 clones 
bevacizumab treatment. B,
xenograft growth curves of HT29wt
 acetazolamide (ATZ) 
bevacizumab treatment. C,
xenograft growth curves of U87
doxycycline (Dox)-inducible shCTL
 Dox and shCA9  Dox
xenografts. D, xenograft growth
curves of U87 doxycycline
(Dox)-inducible shCA9  Dox 
bevacizumab. Arrows denote the
start of bevacizumab treatment
and/or acetazolamide treatment at
150 mm3 xenograft volume.
(, P < 0.001; , P < 0.01;
, P < 0.05, n ¼ 5).
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surprising as we initially expected CAIX to reduce necrosis
by improving intracellular pH control. The overall effect of
this was increased tumor volume with more viable tumor
and more necrosis at the same time point in the CAIX
expressors, of both HCT116 and HT29 cell lines. The
increase in apoptosis associated with CAIX offers a mech-
anism to explain the increased pathologic necrosis.
We hypothesize that the necrosis may represent regions
where CAIX expression has maintained a high level of
proliferation (as shown in Fig. 5A) through the mainte-
nance of a more uniformly alkaline intracellular pH. This
would increasemetabolic demand anddeplete substrates in
the hypoxic milieu. We previously identified that necrosis
also induces infiltration of macrophages which may con-
tribute to an aggressive tumor phenotype (44, 45) and
necrosis is associated with poor prognosis in many cancer
types including colorectal cancer (46). So the well-recog-
nized observation of CAIX staining around necrotic areas
may reflect a causative role in necrosis.
CAIX expression was associated with Ki-67 positivity in
HT29, particularly in the hypoxic areas in HT29 spheroids.
This is in agreement with data that CAIX maintains an
intracellular environment conducive for growth under hyp-
oxic conditions. CAIX expression increased growth in
HCT116 spheroids and xenografts, however there was no
difference in Ki-67 staining. While Ki-67 stains positive
proliferative cells, staining does not relate to the time
required for an intermitotic cycle completion (47).
A recent study identified CAXII upregulation in response
to CAIX knockdown in 2D culture at the RNA and protein
level (30). We have identified CAXII upregulation in
response to CAIX knockdown in spheroids and in vivo, but
not in 2D culture. The cause of this difference requires
further study, but it may be related to differences in pH or
oxygen tension between 2D and 3D culture.
We investigated CAIX knockdown in combination with
antiangiogenic therapy (bevacizumab) in 2 tumor types.
CAIXwas recently associatedwith poor outcome in patients
with metastatic colorectal treated with bevacizumab (27).
Here, we show that CAIX knockdown and bevacizumab
treatment acted additively in reducing xenograft growth rate
in the colon adenocarcinoma cell line HT29 and synergis-
tically in the glioblastoma cell line U87. In addition, the CA
inhibitor acetazolamide enhanced bevacizumab treatment
in HT29 xenografts. Our results provide experimental evi-
dence that is consistent with previous immunohistologic
data (27–29), showing that CAIX is part of a resistance
mechanism that enables tumors to adapt to the increased
hypoxia inducedbybevacizumab treatment.On the basis of
these data, detection of CAIX induction levels, possibly
detected in blood serum or urine (48), in response to
bevacizumab could help in predicting outcome to bevaci-
zumab treatment. This highlights also the general principle
of targeting the hypoxia survival mechanisms in combina-
tion with bevacizumab treatment, particularly given the
chemotherapy and radiotherapy resistance of such hypoxic
areas.
The effect of CAIX knockdown, reducing xenograft
tumor growth alone, and at least additively in combina-
tion with antiangiogenic therapy, and the association
between CAIX expression and increased necrosis, identi-
fying a further mechanism to explain CAIX association
with poorer outcome, highlight potential mechanisms by
which CAIX inhibitory therapeutics, such as antibodies
(49) and small-molecular inhibitors (50), may be used
optimally.
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